Trial · NCT01840072
China Antihypertensive Trial in Acute Ischemic Stroke
NCT01840072, Not applicable, Completed, Tulane University; results first posted 2014-11-20
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. China Antihypertensive Trial in Acute Ischemic Stroke. Trials, record NCT01840072. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01840072
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- China Antihypertensive Trial in Acute Ischemic Stroke
- NCT number
- NCT01840072
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4,071 participants, actual
- Lead sponsor
- Tulane University
- Conditions
- Ischemic Stroke
- Interventions
- Active antihypertensive treatment
- First posted
- 2013-04-25
- Last updated
- 2024-03-27
- Results first posted
- 2014-11-20
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. | 2 weeks | Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. |
| Secondary | A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. | 3 months | Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death |
| Secondary | Mortality | 3 months | Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. |
| Secondary | Recurrent Stroke | 3 months | Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. |
| Secondary | Other Vascular Events | 3 months | Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. |
| Secondary | Long-term Neurological and Functional Status | Three months | Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. |
| Secondary | Cognitive Function (the Mini-Mental State Examination) | Three months | Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). |
| Secondary | Cognitive Function (Montreal Cognitive Assessment) | Three months | Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education \<12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of \<26. |
| Secondary | Quality of Life | 3 months | Due to limited funding, quality of life data were not collected. |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. | 2 weeks | participants | NUMBER | |
| SECONDARY | A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. | 3 months | All participants examined at 3-month posttreatment follow-up visit | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mortality | 3 months | All participants followed at 3-month posttreatment follow-up visit | participants | NUMBER |
| SECONDARY | Recurrent Stroke | 3 months | participants | NUMBER | |
| SECONDARY | Other Vascular Events | 3 months | participants | NUMBER | |
| SECONDARY | Long-term Neurological and Functional Status | Three months | Those patients who are still alive and followed at 3-Month posttreatment follow-up visit | Score on modified Rankin scale | MEDIAN |
| SECONDARY | Cognitive Function (the Mini-Mental State Examination) | Three months | In a pre-planned ancillary study, 660 participants were systemically selected prior to randomization for cognitive function assessment. At the 3-month visit, 15 patients were lost to follow-up and 7 patients were deceased. A total of 638 participants who completed the cognitive function tests were included in this analysis. | MMSE score | MEDIAN |
| SECONDARY | Cognitive Function (Montreal Cognitive Assessment) | Three months | In a pre-planned ancillary study, 660 participants were systemically selected prior to randomization for cognitive function assessment. At the 3-month visit, 15 patients were lost to follow-up and 7 patients were deceased. A total of 638 participants who completed the cognitive function tests were included in this analysis. | MoCA score | MEDIAN |
| SECONDARY | Quality of Life | 3 months |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. | Usual Care | 681 | participants | ||
| A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. | Active Antihypertensive Treatment | 683 | participants | ||
| A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. | Usual Care | 502 | Participants | ||
| A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. | Active Antihypertensive Treatment | 500 | Participants | ||
| Mortality | Active Antihypertensive Treatment | 68 | participants | ||
| Mortality | Usual Care | 54 | participants | ||
| Recurrent Stroke | Active Antihypertensive Treatment | 28 | participants | ||
| Recurrent Stroke | Usual Care | 43 | participants | ||
| Other Vascular Events | Usual Care | 59 | participants | ||
| Other Vascular Events | Active Antihypertensive Treatment | 48 | participants |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Active Antihypertensive Treatment | 2,038 | |
| Overall Study | STARTED | Usual Care | 2,033 | |
| Overall Study | COMPLETED | Active Antihypertensive Treatment | 2,031 | |
| Overall Study | COMPLETED | Usual Care | 1,986 | |
| Overall Study | NOT COMPLETED | Active Antihypertensive Treatment | 7 | |
| Overall Study | NOT COMPLETED | Usual Care | 47 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Active Antihypertensive Treatment | ||
| Total, all-cause mortality | Usual Care | ||
| Total, other adverse events | Active Antihypertensive Treatment | 0 | 2,038 |
| Total, other adverse events | Usual Care | 0 | 2,033 |
| Total, serious adverse events | Active Antihypertensive Treatment | 0 | 2,038 |
| Total, serious adverse events | Usual Care | 0 | 2,033 |
Source ClinicalTrials.gov
Papers36
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Active Antihypertensive Treatment vs Usual Care: Recurrent Stroke | Trial comparisons |
| Active Antihypertensive Treatment vs Usual Care: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. | Trial comparisons |
| Active Antihypertensive Treatment vs Usual Care: Other Vascular Events | Trial comparisons |
| Active Antihypertensive Treatment vs Usual Care: Mortality | Trial comparisons |
| Active Antihypertensive Treatment vs Usual Care: A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. | Trial comparisons |
| Active Antihypertensive Treatment vs Usual Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01840072
GET https://conductscience.org/api/trials/v1/NCT01840072/papers?page=2